Skip to main content

High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?

We read with great interest the article by De Pascale et al. who show that the use of high doses (200 mg loading dose followed by 100 mg two times a day) of tigecycline (TGC) is associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria [1]. One-third of the patients in the study had acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT), yet the authors claim that losses of tigecycline via CRRT were negligible, based entirely upon the work of Broeker et al. [2]. We would like to make some comments. First, the CRRT modality chosen by Broeker et al. [2] may have influenced TGC elimination. TGC clearance during continuous veno-venous hemodiafiltration (CVVHDF) was more efficient (2.71 L/h) as compared to continuous veno-venous hemodialysis (CVVHD, 1.69 L/h) [2]. Second, Broeker et al. attribute the increased clearance of TGC with CVVHDF to low plasma protein binding (recently reported as 50–70%, compared to the previously reported 11–29%), allowing better elimination through ultrafiltration [2]. This increased ultrafiltration yields a saturation coefficient of 0.79 for CVVHD and 0.90 for CVVHDF and probably higher for continuous veno-venous hemofiltration (CVVH) [2]. The removal by CVVHDF and CVVHD yield together a value of 11.2% [2]. If we look at CVVHD alone (1.69 L/h), this represents only 9% of the total body clearance (18.3 L/h) [2]. Looking at CVVHDF (2.71 L/h), this represents almost 15%. Third, TGC protein binding is affected by divalent cations such as calcium, and accordingly, regional citrate anticoagulation (RCA) might affect membrane transfer [2]. This would be suspected if convection was used in the study as it is more protein binding dependent. RCA was only used in CVVHD and not in CVVHDF, where unfractionated heparin (UHF) was used [2]. Fourth, TGC can be adsorbed by plastic labware [3] and there is a great suspicion that TGC could be adsorbed by highly adsorptive membranes (HAM) [4]. Broeker et al. used a polysulfone membrane which is poorly adsorptive; nevertheless, in their study, they observed a time delay in the effluent concentrations in one patient that may have been caused by adsorption losses inside the membrane [2]. They concluded that since the delay indicated a saturable binding, adsorption losses did not impact the dialysis clearance significantly [2]. We respectfully disagree, as most of the adsorption of small molecules does not occur at the surface of the membrane, but rather occurs inside the membrane fibers and therefore it takes more time to become saturated [5]. Indeed, Tian et al. clearly demonstrated that the absence of saturation could exclude surface adsorption, as repeated doses of amikacin resulted in further bulk adsorption [5]. Comparing the pharmacokinetics/pharmacodynamics (PK/PD) between the Broeker and the De Pascale studies, the PK/PD was much more optimal in the Broeker study, again suggesting that even higher doses may be needed in CRRT patients. It would be interesting to know which CRRT modality, type of membrane and anticoagulation were used in the De Pascale study, in order to further elucidate the effect of CRRT on the PK/PD. Overall, the conclusion that no dose adjustment is necessary during CRRT seems somewhat premature. At this time, we cannot rule out the possibility that using a higher dose such as 100 mg three times a day in patients receiving CRRT may further improve PK/PD and perhaps related mortality.

Availability of data and materials

Not applicable.

Abbreviations

TGC:

Tigecycline

CRRT:

Continuous renal replacement therapies

CVVVHDF:

Continuous veno-venous hemodiafiltration

CVVHD:

Continuous veno-venous hemodialysis

CVVH:

Continuous veno-venous hemofiltration

RCA:

Regional citrate anticoagulation

UFH:

Unfractionated heparin

PK/PD:

Pharmacokinetics/pharmacodynamics

References

  1. 1.

    De Pascale G, Lisi L, Ciotti GMP, et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020;10(1):94. https://doi.org/10.1186/s13613-020-00715-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Crit Care. 2018;22:341. https://doi.org/10.1186/s13054-018-2278-4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Dorn C, Kratzer A, Liebchen U, et al. Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration. J Pharm Sci. 2018;107:739–44. https://doi.org/10.1016/j.xphs.2017.09.006.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Honoré PM, De Bels D, Spapen HD. An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock. Curr Opin Crit Care. 2018;24(6):463–8. https://doi.org/10.1097/MCC.0000000000000542.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008;52(3):1009–13. https://doi.org/10.1128/aac.00858-07.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. Melissa Jackson for critical review of the manuscript.

Funding

None.

Author information

Affiliations

Authors

Contributions

PMH, SR, DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Patrick M. Honore.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare to have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Barreto Gutierrez, L., Kugener, L. et al. High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?. Ann. Intensive Care 10, 139 (2020). https://doi.org/10.1186/s13613-020-00758-5

Download citation